Overall our data suggest that human clinical trials evaluating the benefits of α-IL-6 mAbs versus α-IL-6R mAbs titversus combined early α-IL-6 mAb and later α-IL-6R mAb is warranted to evaluate the potential of IL-6 pathway blockade in the during Ebola or SARS-CoV-2 infection. This evidence concerns the gene IL6 and Ebola hemorrhagic fever.